| Literature DB >> 8744561 |
D W Vaughn1, C H Hoke, S Yoksan, R LaChance, B L Innis, R M Rice, N Bhamarapravati.
Abstract
A live-attenuated dengue 2 vaccine (strain 16681 PDK 53) developed at Mahidol University, Thailand was evaluated for safety and immunogenicity by administering 10(4) p.f.u. subcutaneously to ten flavivirus non-immune American volunteers. The vaccine was safe; there were no serious adverse reactions. Eight recipients experienced no or mild side effects. One recipient reported headaches on 7 separate days. One volunteer, who had a fracture of the humerus 1 day after vaccination requiring surgical repair, experienced generalized malaise with fever (maximum temperature = 38.9 degrees C), headache, eye pain and myalgia lasting less than 24 h. The vaccine was highly immunogenic; all recipients developed neutralizing antibody that persisted for two years.Entities:
Mesh：
Substances：
Year: 1996 PMID： 8744561 DOI： 10.1016/0264-410x(95)00167-y
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641